Angiogenesis and targeted therapy in the tumour microenvironment: From basic to clinical practice

IF 7.9 1区医学 Q1 MEDICINE, RESEARCH & EXPERIMENTAL

Clinical and Translational Medicine Pub Date : 2025-04-23 DOI:10.1002/ctm2.70313

Shuaixi Yang, Yingshuai Fang, Yangcheng Ma, Fuqi Wang, Yuhang Wang, Jiachi Jia, Yabing Yang, Weipeng Sun, Quanbo Zhou, Zhen Li

{"title":"Angiogenesis and targeted therapy in the tumour microenvironment: From basic to clinical practice","authors":"Shuaixi Yang, Yingshuai Fang, Yangcheng Ma, Fuqi Wang, Yuhang Wang, Jiachi Jia, Yabing Yang, Weipeng Sun, Quanbo Zhou, Zhen Li","doi":"10.1002/ctm2.70313","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <p>Angiogenesis, as a core marker of cancer survival and growth, is integral to the processes of tumour growth, invasion and metastasis. In recent years, targeted angiogenesis treatment strategies have gradually become an important direction in cancer treatment. Single-cell sequencing technology can provide new insights into targeted angiogenesis by providing a deeper understanding of the heterogeneity of tumour endothelial cells and exploring the interactions between endothelial cells and surrounding cells in the tumour microenvironment. Here, we systematically review the research progress in endothelial cell pathophysiology and its endothelial‒mesenchymal transition and illustrate the heterogeneity of endothelial cells from a single-cell perspective. Finally, we examine the contributions of different cell types within the tumour microenvironment in relation to tumour angiogenesis, as well as the latest progress and strategies in targeted angiogenesis therapy, hoping to provide useful insights into the clinical application of antiangiogenic treatment. Furthermore, a summary of the present progress in the development of potential angiogenesis inhibitors and the ongoing clinical trials for combination therapies is provided.</p>\n </section>\n \n <section>\n \n <h3> Key points</h3>\n \n <div>\n <ul>\n \n <li>Angiogenesis plays a key role in tumour progression, invasion and metastasis, so strategies targeting angiogenesis are gradually becoming an important direction in cancer therapy.</li>\n \n <li>Interactions between endothelial cells and stromal cells and immune cells in the tumour microenvironment are significant in angiogenesis.</li>\n \n <li>The application of antiangiogenic immunotherapy and nanotechnology in antiangiogenic therapy provides a vital strategy for prolonging the survival of cancer patients.</li>\n </ul>\n </div>\n </section>\n </div>","PeriodicalId":10189,"journal":{"name":"Clinical and Translational Medicine","volume":"15 4","pages":""},"PeriodicalIF":7.9000,"publicationDate":"2025-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ctm2.70313","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Translational Medicine","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/ctm2.70313","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

Angiogenesis, as a core marker of cancer survival and growth, is integral to the processes of tumour growth, invasion and metastasis. In recent years, targeted angiogenesis treatment strategies have gradually become an important direction in cancer treatment. Single-cell sequencing technology can provide new insights into targeted angiogenesis by providing a deeper understanding of the heterogeneity of tumour endothelial cells and exploring the interactions between endothelial cells and surrounding cells in the tumour microenvironment. Here, we systematically review the research progress in endothelial cell pathophysiology and its endothelial‒mesenchymal transition and illustrate the heterogeneity of endothelial cells from a single-cell perspective. Finally, we examine the contributions of different cell types within the tumour microenvironment in relation to tumour angiogenesis, as well as the latest progress and strategies in targeted angiogenesis therapy, hoping to provide useful insights into the clinical application of antiangiogenic treatment. Furthermore, a summary of the present progress in the development of potential angiogenesis inhibitors and the ongoing clinical trials for combination therapies is provided.

Key points

Angiogenesis plays a key role in tumour progression, invasion and metastasis, so strategies targeting angiogenesis are gradually becoming an important direction in cancer therapy.
Interactions between endothelial cells and stromal cells and immune cells in the tumour microenvironment are significant in angiogenesis.
The application of antiangiogenic immunotherapy and nanotechnology in antiangiogenic therapy provides a vital strategy for prolonging the survival of cancer patients.

Abstract Image

查看原文本刊更多论文

肿瘤微环境中的血管生成和靶向治疗：从基础到临床实践

血管生成是肿瘤生存和生长的核心标志，是肿瘤生长、侵袭和转移过程中不可或缺的一部分。近年来，靶向血管生成治疗策略逐渐成为肿瘤治疗的重要方向。单细胞测序技术可以通过更深入地了解肿瘤内皮细胞的异质性和探索肿瘤微环境中内皮细胞与周围细胞之间的相互作用，为靶向血管生成提供新的见解。本文系统综述了内皮细胞病理生理及其内皮-间质转化的研究进展，并从单细胞角度阐述了内皮细胞的异质性。最后，我们研究了肿瘤微环境中不同类型细胞对肿瘤血管生成的贡献，以及靶向血管生成治疗的最新进展和策略，希望为抗血管生成治疗的临床应用提供有用的见解。此外，本文还总结了目前潜在血管生成抑制剂的开发进展和正在进行的联合治疗的临床试验。血管生成在肿瘤的进展、侵袭和转移中起着关键作用，因此针对血管生成的策略逐渐成为肿瘤治疗的重要方向。肿瘤微环境中内皮细胞、基质细胞和免疫细胞之间的相互作用在血管生成中具有重要意义。抗血管生成免疫治疗和纳米技术在抗血管生成治疗中的应用为延长癌症患者的生存期提供了重要的策略。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical and Translational Medicine Multiple-

CiteScore

15.90

自引率

1.90%

发文量

450

审稿时长

4 weeks

期刊介绍： Clinical and Translational Medicine (CTM) is an international, peer-reviewed, open-access journal dedicated to accelerating the translation of preclinical research into clinical applications and fostering communication between basic and clinical scientists. It highlights the clinical potential and application of various fields including biotechnologies, biomaterials, bioengineering, biomarkers, molecular medicine, omics science, bioinformatics, immunology, molecular imaging, drug discovery, regulation, and health policy. With a focus on the bench-to-bedside approach, CTM prioritizes studies and clinical observations that generate hypotheses relevant to patients and diseases, guiding investigations in cellular and molecular medicine. The journal encourages submissions from clinicians, researchers, policymakers, and industry professionals.